Genprex (GNPX) Total Liabilities (2016 - 2026)
Genprex (GNPX) posted quarterly Total Liabilities of $3.4 million for Q1 2026, down 43.82% year-over-year from $6.0 million in Q1 2025, and up 53.65% quarter-over-quarter from $2.2 million in Q4 2025.
Genprex (GNPX) Total Liabilities (2016 - 2026) Analysis & Trends
Genprex's Total Liabilities history runs 11 years deep, the most recent figure standing at $3.4 million for Q1 2026.
- In Q1 2026, Total Liabilities fell 43.82% year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $3.4 million (down 43.82% YoY), while the FY2025 annual figure was $2.2 million, down 12.26% from the prior year.
- Total Liabilities for Q1 2026 stood at $3.4 million, up from $2.2 million in the prior quarter.
- The five-year high for Total Liabilities was $25.1 million in Q4 2022, with the low at $2.2 million in Q2 2022.
- The 5-year median for Total Liabilities is $3.9 million (2024), against an average of $8.4 million.
- Peak annual rise in Total Liabilities reached 1482.36% in 2022, while the deepest fall reached 95.58% in 2022.
- Genprex's Total Liabilities stood at $25.1 million in 2022, then slumped by 57.46% to $10.7 million in 2023, then slumped by 76.53% to $2.5 million in 2024, then dropped by 12.26% to $2.2 million in 2025, then soared by 53.65% to $3.4 million in 2026.
- Business Quant data shows GNPX's Total Liabilities at $3.4 million in Q1 2026, $2.2 million in Q4 2025, and $2.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Genprex | 1.88 Mn | -13.28 Mn | - | 2.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.38 Mn |
| Dec 31, 2025 | 2.20 Mn |
| Sep 30, 2025 | 2.79 Mn |
| Jun 30, 2025 | 3.83 Mn |
| Mar 31, 2025 | 6.01 Mn |
| Dec 31, 2024 | 2.50 Mn |
| Sep 30, 2024 | 3.91 Mn |
| Jun 30, 2024 | 6.60 Mn |
| Mar 31, 2024 | 12.56 Mn |
| Dec 31, 2023 | 10.67 Mn |
| Sep 30, 2023 | 16.64 Mn |
| Jun 30, 2023 | 15.91 Mn |
| Mar 31, 2023 | 23.32 Mn |
| Dec 31, 2022 | 25.09 Mn |
| Sep 30, 2022 | 2.46 Mn |
| Jun 30, 2022 | 2.15 Mn |
| Mar 31, 2022 | 2.38 Mn |
| Dec 31, 2021 | 1.59 Mn |
| Sep 30, 2021 | 46.33 Mn |
| Jun 30, 2021 | 48.73 Mn |